Tikun Europe is establishing its new subsidiary company, Tikun Europe Netherlands BV in Amsterdam.
Tikun Europe Netherlands BV will take responsibility for the marketing, sale and distribution of medical cannabis cultivator and processor Tikun Europe’s CBD in the European market.Â
The CBD product will initially be launched in Greece in the spring, and will contain new CBD products developed by the R&D team at of TIKUN Europe, based in Greece. The R&D unit has created original CBD product formulas, manufactured in a certified factory in France.
Following the official announcement of TIKUN Europe Netherlands BV founding, Nikos Beis, TIKUN Europe’s CEO, stated: “The new company will provide significant support and expertise and will assist Tikun in developing its business across Europe.
“At the same time, it will also help us to respond to the extensive demands of a constantly growing market. Our aim is to provide European consumers with the most innovative, quality products that relate to their personal health and wellness needs and assist them in improving the quality of their everyday life.
“Therefore, TIKUN Europe Netherlands BV operation is not only a business milestone for us at this stage, but also brings us closer to achieving this vital goal.”
Tikun Europe cultivates, processes and merchandises medical as well as industrial cannabis from its 56,000 square meters site, west of Athens, Corinth.
The company has stated its activity is fully aligned with the Greek legislation provisions for the cultivation and processing of medical cannabis, aiming at the creation of pharmaceutical formulations that are produced in a GMP environment.Â
The company began its journey in 2005 with the establishment of Tikun Israel and has grown across the US, Canada and Europe – establishing Canada’s MedReleaf in 2014 which was acquired by Aurora in 2018, Tikun USA in 2016, Medifarm-Tikun Oceania in 2017, and finally Tikun Europe in 2018.Â
Last year the company expanded its pharmaceutical footprint with the announcement of a new partnership with Wavelength Pharmaceuticals, owned by US investment firm SK Capital Partners, which will see the pair jointly develop, manufacture and market active cannabis-based raw materials for the pharmaceutical industry.
[activecampaign form=31]
